Interviews and Presentations


Batu Biologics #starvethetumor Campaign Launch Press Conference

Batu Biologics hosted a press conference announcing the launch of an equity crowdfunding campaign to fund the development of the ValloVax program. The company is raising funds from accredited investors that will be allocated towards efforts to receive regulatory approval from the FDA to use ValloVax in the clinical setting for the treatment of cancer. More information about the campaign can be viewed at


Batu Biologics EquityNet #starvethetumor Video

A brief video summarizing the journey of the Company, our plans for the development of the ValloVax program, and an introduction to some key members of the Team. Learn more about the #starvethetumor offering open to accredited investors at:


Batu Biologics EquityNet #starvethetumor Animation

An introduction to Batu Biologics mission and Technology. Learn more about the #starvethetumor offering open to accredited investors at:


Pioneering New Frontiers in Tumor Angiogenesis

An excellent video providing an overview of tumor angiogeneis. The blood vessels associated with the tumor are genetically stable and therefore less likely to mutate and develop resistance to therapy.


Batu Biologics Presents at Spotlight on JLABS Event

Batu Biologics was selected as one of the highlighted companies from the JLABS incubator facility in San Diego, CA. Mr. Samuel Wagner, President and CEO, discusses the company’s unique approach to treating cancer by targeting the tumor blood vessels with a potent, multi-pronged active vaccination.


Batu Biologics Introduces ValloVax Immunotherapy

Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer”: the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics has currently filed an Investigational New Drug Application (IND # 16296) for the initial indication of non-small cell lung cancer (NSCLC), and anticipates clinical approval to begin treating patients in Q3 of 2015.


Anti-angiogenic cancer vaccinations – a promising future for cancer immunotherapy

Samuel C. Wagner, President and CEO of Batu Biologics, discusses Facciponte’s study of a TEM-1 DNA vaccination’s efficacy as a cancer therapeutic and the affect of the vaccination on healthy angiogenesis processes in the body.


Batu Biologics Launches Indiegogo Crowdfunding Campaign for Novel Lung Cancer Therapy

Batu Biologics is pleased to announce the launch of its first crowdfunding campaign asking $100,000 to complete the preclinical studies for ValloVax, a novel cancer vaccine targeting the tumor blood vessels (endothelium).


Tumor Blood Vessels: Cancer’s Shield Against the Immune System?

Samuel Wagner, President and CEO of Batu Biologics, discusses the significance of the tumor endothelium as the first immunological barrier masking the tumor from detection and destruction by the host’s immune system.